171 related articles for article (PubMed ID: 22530992)
1. Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey.
Kodama Y; Morozumi R; Matsumura T; Kishi Y; Murashige N; Tanaka Y; Takita M; Hatanaka N; Kusumi E; Kami M; Matsui A
BMC Cancer; 2012 Apr; 12():152. PubMed ID: 22530992
[TBL] [Abstract][Full Text] [Related]
2. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
3. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
4. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
5. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting.
Saleh MN; Haislip S; Sharpe J; Hess T; Gilmore J; Jackson J; Sail KR; Ericson SG; Chen L
Curr Med Res Opin; 2014 Apr; 30(4):529-36. PubMed ID: 24156689
[TBL] [Abstract][Full Text] [Related]
6. Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.
Shepherd P; Dhanapala C; Maguire C; White J; Drummond M; Holyoake T; Johnson PR
Scott Med J; 2008 Aug; 53(3):8-12. PubMed ID: 18780518
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
8. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
9. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
10. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
11. Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia.
Gutierrez-Aguirre CH; Garcia-Rodriguez F; Ortiz-Galvez VM; Cantu-Rodriguez OG; Salazar-Riojas R; Martinez-Gonzalez OL; Gonzalez-Llano O; Jaime-Pérez JC; Ortiz-Lopez R; Flores-Jimenez JA; Alatorre-Ricardo J; Mancias-Guerra C; Gomez-Almaguer D
Hematology; 2013 Jul; 18(4):224-9. PubMed ID: 23433657
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
[TBL] [Abstract][Full Text] [Related]
13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
15. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Branford S; Yeung DT; Ross DM; Prime JA; Field CR; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Sullivan B; Briggs NE; Hertzberg M; Seymour JF; Reynolds J; Hughes TP
Blood; 2013 May; 121(19):3818-24. PubMed ID: 23515925
[TBL] [Abstract][Full Text] [Related]
16. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Bashir Q; De Lima MJ; McMannis JD; Garcia-Manero G; Shpall E; Kantarjian H; Cortes JE; O'Brien SM; Jones D; Qazilbash M; Wei W; Giralt SA; Champlin RE; Hosing C
Leuk Lymphoma; 2010 Aug; 51(8):1478-84. PubMed ID: 20658954
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Cervantes F; Hernández-Boluda JC; Odriozola J; Camós M; Villalón L; Martínez-Climent JA; del Campo R; García-Conde J; Montserrat E
Br J Haematol; 2003 Feb; 120(3):500-4. PubMed ID: 12580969
[TBL] [Abstract][Full Text] [Related]
19. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
[TBL] [Abstract][Full Text] [Related]
20. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S.
Chihara D; Ito H; Matsuda T; Katanoda K; Shibata A; Saika K; Sobue T; Matsuo K
Oncologist; 2012; 17(12):1547-50. PubMed ID: 22971523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]